All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-001246-33 | An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201 or TMC114-C207. | 2009-03-12 | due-trials |
| Reported results | 2004-001657-29 | A Phase II, randomized, active controlled, open label trial to investigate the efficacy and tolerability of TMC125 in HIV-1 infected subjects, who are PI-naïve and with documented genotypic evidence o... | 2006-07-13 | due-trials |
| Reported results | 2004-001658-10 | An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor selected TMC125 trial to an active control arm and either virologically failed or completed the entire treat... | 2007-03-20 | due-trials |
| Reported results | 2004-002202-30 | An open label study to evaluate the effects on Mycobacterium tuberculosis, safety, tolerability and pharmacokinetics of single doses of R207910, in treatment naive patients with mycobacterium tubercul... | 2006-02-01 | due-trials |
| Reported results | 2004-004055-19 | A Phase IIb randomized, partially blinded, dose-finding trial of TMC278 in antiretroviral naive HIV-1 infected subjects. | 2011-12-15 | due-trials |
| Completed, but no date, and reported results | 2004-004990-27 | The pharmacokinetic interaction between TMC114, lopinavir and ritonavir, in HIV-1 infected subjects. | bad-data | |
| Reported results | 2004-005142-12 | An open-label study to evaluate the extended early bactericidal activity, safety, tolerability and pharmacokinetics of multiple doses (m.d.) of TMC207 oral solution (os) and isoniazid (JH), m.d. of TM... | 2006-02-01 | due-trials |
| Reported results | 2005-000594-22 | A radomized, controlled, open-label trial to compare the efficacy, safety, and tolerability of TMC114/RTV versus LPV/RTV in treatmet- experienced HIV-1 infected subjects. | 2011-10-06 | due-trials |
| Reported results | 2005-000712-27 | An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks. | 2008-08-30 | due-trials |
| Reported results | 2005-000793-45 | Open-label safety study of TMC114 in combination with low dose RTV and other ARVs in highly experienced HIV-1 infected patients with limited or no treatment options | 2007-06-06 | due-trials |
| Reported results | 2005-002437-13 | Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. | 2009-09-29 | due-trials |
| Reported results | 2005-002486-36 | A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. | 2012-05-08 | due-trials |
| Reported results | 2005-003145-13 | A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR ... | 2008-08-13 | due-trials |
| Reported results | 2005-003160-32 | A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR... | 2008-08-12 | due-trials |
| Trial is partly outside EEC, and reported results | 2005-006179-11 | A Phase II, open-label trial, to investigate pharmacokinetics, safety, tolerability and antiviral activity of TMC114/rtv b.i.d. in treatmentexperienced HIV-1 infected children and adolescents. | 2007-03-19 | bad-data |
| Reported results | 2006-001287-23 | An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator selected OBR in HIV-1 infected subjects who participated in a DUET trial TMC125-C206 or TMC125-C216 | 2012-01-24 | due-trials |
| Exempt, with results | 2006-002183-26 | A Phase I, open-label trial to investigate pharmacokinetics, safety and tolerability of TMC125 at steady-state in treatment-experienced HIV-1 infected children. | 2008-02-27 | not-yet-due |
| Completed, but no date, and reported results | 2006-002499-16 | Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options. | bad-data | |
| Completed, but no date | 2006-003439-53 | A double blind, randomized, placebo-controlled study to evaluate the antiviral activity, safety and plasma pharmacokinetics of multiple intravenous doses of TMC353121 in hematopoietic stem cell transp... | bad-data | |
| Reported results | 2007-001044-44 | A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys) and ribavirin (Copegus) or Peg-IFN alfa2b (P... | 2009-09-14 | due-trials |
| Reported results | 2007-001939-61 | A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects... | 2011-10-05 | due-trials |
| Reported results | 2007-002646-38 | A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricita... | 2011-12-15 | due-trials |
| Reported results | 2007-002647-25 | A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibito... | 2012-02-08 | due-trials |
| Reported results | 2007-002920-14 | A Phase IIa randomized, partially blinded trial of telaprevir (VX-950) in treatment-naïve subjects with chronic genotype 2 or 3 hepatitis C infection | 2009-05-28 | due-trials |
| Reported results | 2007-003289-16 | A blinded, randomized, placebo-controlled trial in genotype 1 hepatitis C-infected subjects to evaluate the efficacy, safety, tolerability and pharmacokinetics of repeated doses of TMC435350, with or ... | 2010-05-10 | due-trials |
| Reported results | 2007-004462-40 | A Phase II, placebo-controlled, double-blind, randomized trial to evaluate the anti-bacterial activity, safety, and tolerability of TMC207 in subjects with sputum smear-positive pulmonary infection wi... | 2012-10-09 | due-trials |
| Reported results | 2007-005281-12 | A Phase IIa randomized, partially blinded trial of telaprevir (VX-950) in treatment-naïve subjects with chronic genotype 4 hepatitis C infection | 2010-01-11 | due-trials |
| Reported results | 2007-007086-21 | A Phase II, open-label trial to evaluate the safety, tolerability and antiviral activity of TMC125 in antiretroviral experienced HIV-1 infected children and adolescents | 2011-08-30 | due-trials |
| Reported results | 2008-000533-22 | A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copeg... | 2010-07-16 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-001696-30 | A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral naive HIV1 infected adolescents and ch... | bad-data | |
| Trial is outside EEC, and reported results | 2008-004630-25 | A Phase II, open label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV in combination with low-dose ritonavir (DRV/rtv) in treatment-experienced HIV-1 infected ... | bad-data | |
| Trial is partly outside EEC, and reported results | 2008-004631-37 | A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 yea... | 2011-03-31 | bad-data |
| Reported results | 2008-005709-20 | An open-label trial in genotype 2, 3, 4, 5 and 6 hepatitis C-infected subjects to evaluate the antiviral activity, safety, tolerability and pharmacokinetics of TMC435350 following 7 days once daily do... | 2009-11-18 | due-trials |
| Other | 2008-006009-18 | An open-label, Proof-of-Concept trial in treatment-naïve HIV-1- infected subjects to evaluate the antiviral activity of a single intramuscular dosing of TMC278LA as monotherapy. | not-yet-due | |
| Reported results | 2008-007147-13 | A Phase IIb, randomized, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including peginterferon ... | 2011-04-30 | due-trials |
| Reported results | 2008-008190-58 | A Phase IIa, open-label, randomized trial in treatment-naïve HIV-1-infected subjects to determine the antiviral activity of 14 days of monotherapy with 4 different dose regimens of TMC310911 co-admini... | 2011-02-21 | due-trials |
| Reported results | 2009-010590-20 | A Phase IIb, randomized, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including PegIFNα-2a and... | 2011-08-17 | due-trials |
| Reported results | 2009-010887-41 | A randomized, exploratory, open-label 48-week trial with a 2-week Pre-Treatment Phase to investigate the pharmacokinetics, safety, tolerability and antiviral activity of etravirine (ETR) in combinatio... | 2012-04-10 | due-trials |
| Reported results | 2009-012613-21 | An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) for subjects from the control group of the VX-950-TiDP24-C21... | 2012-05-16 | due-trials |
| Ongoing | 2009-013126-16 | Acceso continuado de etravirina en niños y adolescentes infectados por VIH-1 previamente tratados. Continued access to etravirine in treatment experienced HIV-1 infected children and adolescents. | not-yet-due | |
| Reported results | 2009-017013-29 | Acceso continuado a darunavir/ritonavir (DRV/rtv) de niños y adolescentes de 3 o más años de edad infectados por el VIH-1 | 2017-11-23 | due-trials |
| Reported results | 2010-020444-36 | A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2... | 2013-01-29 | due-trials |
| Reported results | 2010-021113-23 | ""Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginterfe... | 2013-02-04 | due-trials |
| Reported results | 2010-021174-11 | A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon α-2... | 2013-02-05 | due-trials |
| Reported results | 2010-021209-18 | "Ensayo abierto con TMC278 25 mg al día en combinación con una pauta de base con dos inhibidores de la transcriptasa inversa nucleosídicos/nucleotídicos en pacientes infectados por el VIH-1 que partic... | 2020-02-28 | due-trials |
| Reported results | 2010-021337-31 | A Phase III open-label study to evaluate the safety, tolerability and efficacy of TMC435 plus PegIFN?-2a (Pegasys)® and ribavirin (Copegus)® triple therapy in chronic hepatitis C genotype-1 infected s... | 2013-08-28 | due-trials |
| Reported results | 2010-021628-84 | A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-na�ve subjects with genoty... | 2012-11-28 | due-trials |
| Reported results | 2011-000416-25 | A Phase III, open-label trial of TMC435 in combination with peginterferon alpha-2a and ribavirin for HCV genotype-1 infected subjects who participated in the placebo group of a Phase II/III TMC435 stu... | 2015-03-31 | due-trials |
| Reported results | 2011-001180-53 | A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C genoty... | 2014-04-28 | due-trials |